Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicover ABLTS:0RPS +0.21%89 3-1 Month Momentum % is 6.24% as of Aug. 21, 2026. GuruFocus rates LTS:0RPS with a GF Score™ of 89/100 and a GF Value™ of kr231.53 (Fairly Valued). The stock has 5 warning signs investors should review. Among 671 Healthcare Providers & Services companies, Medicover AB ranks better than 62.89% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-21), Medicover AB's 3-1 Month Momentum % is 6.24%.
The industry rank for Medicover AB's 3-1 Month Momentum % or its related term are showing as below:
LTS:0RPS's 3-1 Month Momentum % is ranked better than 62.89% of 671
companies
in the Healthcare Providers & Services industry
Industry Median: -1.71
vs LTS:0RPS: 6.24
Medicover AB (LTS:0RPS) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Medicover AB 3-1 Month Momentum % Related Terms
LTS:0RPS vs HCA, THC, DVA: 3-1 Month Momentum % Comparison
For the Medical Care Facilities subindustry, Medicover AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicover AB 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medicover AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Medicover AB's 3-1 Month Momentum % falls into.
Medicover AB (LTS:0RPS) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicover AB (LTS:0RPS) has a 3-1 Month Momentum % of 6.24% as of Aug. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medicover AB and its competitors. According to the industry distribution chart, Medicover AB ranks #249 out of 671 companies in the Healthcare Providers & Services industry, placing it in the top 37.1%.
Is Medicover AB's 3-1 Month Momentum % too high?
Medicover AB's current 3-1 Month Momentum % is 6.24%. Based on the distribution chart, Medicover AB ranks #249 out of 671 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Medicover AB has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medicover AB's 3-1 Month Momentum % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medicover AB ranks #249 out of 671 companies for 3-1 Month Momentum %. This puts Medicover AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medicover AB and its competitors. Medicover AB's current 3-1 Month Momentum % is 6.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicover AB stock overvalued right now?
Based on GuruFocus' analysis, Medicover AB (LTS:0RPS) is currently considered Fairly Valued. The stock's GF Value™ is kr231.53, compared to a current price of kr239.50 — trading 3.4% above its estimated fair value. The current 3-1 Month Momentum % is 6.24%. Medicover AB's overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Medicover AB (LTS:0RPS), the current 3-1 Month Momentum % is 6.24% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicover AB (LTS:0RPS) Overvalued in 2026?
Based on GuruFocus' analysis, Medicover AB stock appears to be overvalued.
The current stock price of kr239.50 is trading 3.4% above its estimated GF Value™ of kr231.53.
GuruFocus considers Medicover AB to be Fairly Valued.
Key valuation signals for LTS:0RPS:
3-1 Month Momentum %: 6.24%
GF Value™: kr231.53 vs. price of kr239.50 (3.4% above fair value)
No single metric tells the full story. See the LTS:0RPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicover AB is an international healthcare and diagnostic services provider. It offers a broad spectrum of healthcare services via an extensive network of ambulatory clinics, hospitals, specialty-care facilities, and laboratories. Medicover offers its services through two reportable segments: Healthcare Services, which generates the maximum revenue, and Diagnostic Services. Diagnostic Services offer a broad range of laboratory testing in all clinical pathology areas, and Healthcare Services offer medical care and related services by operating on an Integrated Healthcare and Fee-For-Service model across different countries. Geographically, the company derives maximum revenue from Germany, and the rest from Poland, India, Ukraine, Romania, and other countries.
89GF Score
Get the complete analysis for LTS:0RPS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RPS has been successfully added to your 
